Background: One of the commonest causes of deaths among men is prostate cancer. The biological behavior of these tumors is associated with their degree of cellular proliferation. Assessment of over-expression of Ki-67 labeling index is an objective measurement of proliferation and its association with Gleason grading can describe the aggressiveness of these cancers. Thus, the present study was undertaken to study the correlation between Ki-67 expression and histopathological grade with serum PSA levels.

Methods: Twenty seven cases of histopathologically proven prostate cancers were studied over a period of 1.5 years and Gleason grade was assigned in each case. Expression of Ki-67 was analyzed using immunohistochemistry.

Results: Of the total 27 cases, Ki-67 was expressed in majority of the moderately and poorly differentiated tuomurs with 18 cases (66.6%) showing strong positivity. 8 cases (29.62%) revealed serum PSA levels above 20 ng/ml. Gleason’s score of more than 7 was seen among 25 cases (92.6%). There was no significant (p>0.05) association of PSA level with Ki-67. However, association of Ki-67 index and Gleason’s Grade was significant (p=0.03).

Conclusion: Proliferative activity determined by Ki-67 reflects the aggressive behaviour of prostate cancers and association with Gleason’s grade can aid in predicting the recurrence and deciding the appropriate therapy.

Keywords: Adenocarcinoma Prostate; Ki-67; PSA; Gleason’s Grade; Prognosis.

1. Roopa Urs AN, Suchita S , Manjunath GV, Hugara Siddalingappa. A Study of Ki-67 Immunostaining in Prostate. Annals of Pathology and Laboratory Medicine 2018; 5(8), 1-4.
2. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS et al., Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. British journal of cancer 2009; 100(6), 888–893.
3. Hirachand S, Dangol U, Pradhanang S, Acharya S. Study of prostatic pathology and its correlation with prostate specific antigen level. Journal of Pathology of Nepal 2017; 7(1), 1074-1077.
4. Lakhey M, Ghimire R, Shrestha R, Bhatta AD. Correlation of serum free prostate- specific antigen level with histological findings in patients with prostatic disease. Kathmandu Univ Med J 2010; 8:158- 63.
5. Josephine A. Clinicopathological study of prostatic biopsies. J Clin Diagn Res 2014; 8:4-6.
6. Lokuhetty MD, Wijsinghe HD, Abeysuriya DT, Samarasinghe UC. Transrectal ultrasound guided prostatic biopsies: a single centre experience in Sri Lanka. Ceylon Med J 2009;54:6-9.
7. Mansoor I. Pattern of prostatic diseases in Saudi Arabia. The internet journal of Pathology. TMISSN 2003;2: 1528-8307.
8. Edoise M. Isiwele, Akanimo Essiet, Godstime I. Irabor. Correlation of digital rectal examination findings with findings on histopathology of the prostate in patients with suspected prostate cancer. International Journal of Contemporary Medical Research 2018;5(7):G12-G16.
9. Murti K, Warli S, Laksmi L.Relations between KI-67 immunohistochemistry expression with histopathology grading and prostate-specific antigen (PSA) values in adenocarcinoma prostate at Dr H. Adam Malik Hospital, Medan Indonesia. Bali Medical Journal 2017; 6(2): 289-293. 
10. Sulik M, Maruszak K, Puchalska J, Misiukiewicz-Poć M Expression of Ki-67 as a proliferation marker in prostate cancer. Pol Ann Med 2011;18(1):12–19.
11. Madani SH,  Ameli  S,  Khazaei  S,  Kanani  M,  Izadi    Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer.  Indian  J  Pathol  Microbiol  2011;54:688-91.
12. Nikoleishvili D, Pertia A, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone‑treated prostate cancer cells. Int Urol Nephrol 2008;40:953‑9.
13. Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S, et al. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann 2015;7:488-93.
14. Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC. Ki‑67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol 1996;49:741‑8.

Dr Prakriti Shukla

Assistant Professor, Department of Pathology, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India